

Botulinum toxin a possible therapeutic option for rosacea

Research indicates the neuromodulator may affect a neurogenic component that influences vascular dysfunction, inflammation and hypersebacaceous activity

May 16, 2014

By John Jesitus

Orlando, Fla. — Botulinum toxin type A (BoNTA) may provide a reasonable therapeutic option for some patients with rosacea, according to experts who spoke at the Orlando Dermatology meeting recently.

“It’s very important for us to be aware that we have a limited understanding of all that botulinum toxin A is doing within the skin,” says Erin Gilbert, M.D., Ph.D. “We have been using it for more than 15 years clinically for its cosmetic benefits, and we have not begun to address the potential therapeutic power of this drug.” Dr. Gilbert is assistant professor of dermatology at SUNY Downstate Medical Center, New York.